A randomized double - blind <font color="blue">placebo_4</font> <font color="blue">-_4</font> <font color="blue">controlled_1</font> cross - over trial of the impact on quality of life of continuing <font color="blue">dexamethasone_3</font> beyond 24   h following <font color="blue">adjuvant_2</font> <font color="blue">chemotherapy_2</font> for breast cancer . 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed nausea and vomiting after <font color="blue">adjuvant_2</font> <font color="blue">chemotherapy_2</font> for breast cancer . Many patients receive <font color="blue">dexamethasone_2</font> but complain of insomnia , anxiety / agitation , and indigestion . The aim was to determine if patients receiving <font color="blue">chemotherapy_2</font> for breast cancer prefer <font color="blue">treatment_1</font> with <font color="blue">dexamethasone_3</font> <font color="blue">or_1</font> <font color="blue">placebo_3</font> for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two <font color="blue">treatments_1</font> <font color="blue">._1</font> In this randomized , double - blind , cross - over trial , we compared <font color="blue">oral_2</font> <font color="blue">dexamethasone_6</font> <font color="blue">(_1</font> <font color="blue">4_1</font> <font color="blue"> _1</font> <font color="blue">mg_1</font> <font color="blue">twice_1</font> <font color="blue">daily_1</font> <font color="blue">for_1</font> <font color="blue">2_1</font> <font color="blue"> _1</font> <font color="blue">days_1</font> <font color="blue">)_1</font> <font color="blue">versus_1</font> <font color="blue">placebo_5</font> for <font color="blue">chemotherapy_1</font> <font color="blue">-_1</font> naïve patients with breast cancer . All patients received <font color="blue">intravenous_1</font> <font color="blue">granisetron_3</font> <font color="blue">and_1</font> <font color="blue">dexamethasone_4</font> <font color="blue">pre_3</font> <font color="blue">-_3</font> <font color="blue">chemotherapy_3</font> <font color="blue">and_2</font> <font color="blue">oral_2</font> <font color="blue">granisetron_4</font> on day 2 . Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1 to 8 . Median age of the 94 women was 51   years ( range 27 - 76 ) : 79 received <font color="blue">fluorouracil_3</font> <font color="blue">/_3</font> <font color="blue">epirubicin_3</font> <font color="blue">/_3</font> <font color="blue">cyclophosphamide_3</font> and 15 received <font color="blue">doxorubicin_3</font> <font color="blue">/_3</font> <font color="blue">cyclophosphamide_3</font> <font color="blue">._3</font> Thirteen withdrew pre - cycle 2 with no differences between arms . Of 80 patients stating a preference , 31 preferred <font color="blue">placebo_2</font> ( 39   % , 95   % CI : 28 - 50   % ) and 37 ( 46   % , 95   % CI : 35 - 58   % ) preferred <font color="blue">dexamethasone_3</font> <font color="blue">;_3</font> 12 had no preference . There were no differences in intensity of vomiting , nausea , or time to onset of vomiting . There was greater decrease in global QOL ( p   =   0.06 ) when patients received <font color="blue">dexamethasone_2</font> <font color="blue">._2</font> No other symptom / QOL domains differed significantly . In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether <font color="blue">dexamethasone_3</font> <font color="blue">or_1</font> <font color="blue">placebo_3</font> was used after <font color="blue">adjuvant_2</font> <font color="blue">chemotherapy_2</font> <font color="blue">._1</font>